Q-omics provides the consensus-scored METTL9 profile across patient tissues and cancer cell-line models. METTL9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, METTL9 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, METTL9 RNA expression shows 19,054 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where METTL9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL9 survival associations across molecular data types. METTL9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL9 RNA expression–survival associations across cancer types. High METTL9 expression shows unfavorable associations in LIHC, ACC and SARC, but favorable associations in KIRC, OV and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for METTL9 RNA expression.
This table summarizes METTL9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for METTL9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL9 shows lower tumor expression in KICH and higher tumor expression in LIHC, KIRC, KIRP, LUAD and COAD. The KICH box plot shows higher METTL9 RNA expression in normal versus tumor tissue (log2 FC = −1.598, t-test p < 0.001).
This table shows molecular features associated with METTL9 in patient tissues and cancer cell lines. In patient samples, METTL9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
